TY - JOUR
T1 - Repeat biopsy in relapsed or refractory diffuse large B cell lymphoma
T2 - a nationwide survey and retrospective study
AU - Berger, Tamar
AU - Geiger, Karyn Revital
AU - Yeshurun, Moshe
AU - Gafter‑Gvili, Anat
AU - Shochat, Tzippy
AU - Gurion, Ronit
AU - Raanani, Pia
AU - Pasvolsky, Oren
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Almost half of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed/refractory (R/R) disease after frontline immunochemotherapy. Although guidelines recommend histological confirmation of R/R disease, repeat biopsies are not always performed. We conducted a two-part study: a nationwide case-vignette survey among treating hematologists, and a single center retrospective analysis. In the survey part, all 64 participating physicians opted not to perform a repeat biopsy in at least one scenario, more often in refractory cases. In the retrospective part, 116 episodes of R/R aNHL among 61 patients were identified. Repeat biopsy was not performed in 72%, more often in refractory episodes, mostly due to low likelihood of alternative diagnoses or problematic location for biopsy. Our study suggests that many patients do not undergo repeat biopsy in R/R DLBCL, especially in refractory cases. Future studies and recommendations should address the necessity of repeat biopsy, according to patient and disease related characteristics.
AB - Almost half of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed/refractory (R/R) disease after frontline immunochemotherapy. Although guidelines recommend histological confirmation of R/R disease, repeat biopsies are not always performed. We conducted a two-part study: a nationwide case-vignette survey among treating hematologists, and a single center retrospective analysis. In the survey part, all 64 participating physicians opted not to perform a repeat biopsy in at least one scenario, more often in refractory cases. In the retrospective part, 116 episodes of R/R aNHL among 61 patients were identified. Repeat biopsy was not performed in 72%, more often in refractory episodes, mostly due to low likelihood of alternative diagnoses or problematic location for biopsy. Our study suggests that many patients do not undergo repeat biopsy in R/R DLBCL, especially in refractory cases. Future studies and recommendations should address the necessity of repeat biopsy, according to patient and disease related characteristics.
KW - Diffuse large B cell lymphoma (DLBCL)
KW - biopsy
KW - diagnosis
KW - refractory
KW - relapsed
UR - http://www.scopus.com/inward/record.url?scp=85131192920&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2081325
DO - 10.1080/10428194.2022.2081325
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35634737
AN - SCOPUS:85131192920
SN - 1042-8194
VL - 63
SP - 2461
EP - 2468
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 10
ER -